Physician profile
Jay Johnson
NPI 1225108103
$781.21
in general payments reported to CMS, 2019-2025
10 companies · $94.14 in 2025
The $94.14 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.19 · 2020: $84.55 · 2021: $49.05 · 2022: $36.45 · 2023: $358 · 2024: $104 · 2025: $94.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galt Pharmaceuticals, LLC | $275.05 | 2023 | Orphengesic Forte, Oravig |
| Alcon Vision LLC | $173.02 | 2019-2025 | Precision 1, Total30, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $126.48 | 2024-2025 | Xdemvy |
| Allergan, INC. | $59.96 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $38.20 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $36.10 | 2019-2022 | |
| Astellas Pharma US INC | $31.86 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $23.18 | 2023 | Tyrvaya |
| Coopervision INC. | $17.36 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.